BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 6216999)

  • 1. Regulation of the C3 nephritic factor stabilized C3/C5 convertase of complement by purified human erythrocyte C3b receptor.
    Daha MR; Kok DJ; Van Es LA
    Clin Exp Immunol; 1982 Oct; 50(1):209-14. PubMed ID: 6216999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protection of the classical and alternative complement pathway C3 convertases, stabilized by nephritic factors, from decay by the human C3b receptor.
    Fischer E; Kazatchkine MD; Mecarelli-Halbwachs L
    Eur J Immunol; 1984 Dec; 14(12):1111-4. PubMed ID: 6240408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A circulating inhibitor of fluid-phase amplification. C3 convertase formation in systemic lupus erythematosus.
    Waldo FB; Forristal J; Beischel L; West CD
    J Clin Invest; 1985 Jun; 75(6):1786-95. PubMed ID: 3159752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. C3 nephritic factor protects bound C3bBb from cleavage by factor I and human erythrocytes.
    Mold C; Medof ME
    Mol Immunol; 1985 May; 22(5):507-12. PubMed ID: 3848661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stabilization of the amplification convertase of complement by monoclonal antibodies directed against human factor B.
    Daha MR; Deelder AM; Van Es LA
    J Immunol; 1984 May; 132(5):2538-42. PubMed ID: 6232321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation of the amplification C3 convertase of human complement by an inhibitory protein isolated from human erythrocyte membrane.
    Fearon DT
    Proc Natl Acad Sci U S A; 1979 Nov; 76(11):5867-71. PubMed ID: 293688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differences between the binding sites of the complement regulatory proteins DAF, CR1, and factor H on C3 convertases.
    Pangburn MK
    J Immunol; 1986 Mar; 136(6):2216-21. PubMed ID: 2419425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of the classical pathway of complement by the C3NeF-stabilized cell-bound amplification convertase.
    Daha MR; van Es LA
    J Immunol; 1979 Mar; 122(3):801-5. PubMed ID: 448075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased enzymatic activity of the alternative pathway convertase when bound to the erythrocytes of paroxysmal nocturnal hemoglobinuria.
    Parker CJ; Baker PJ; Rosse WF
    J Clin Invest; 1982 Feb; 69(2):337-46. PubMed ID: 6915939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanism of action of the C4 nephritic factor. Deregulation of the classical pathway of C3 convertase.
    Gigli I; Sorvillo J; Mecarelli-Halbwachs L; Leibowitch J
    J Exp Med; 1981 Jul; 154(1):1-12. PubMed ID: 7019379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Purification and functional analysis of the polymorphic variants of the C3b/C4b receptor (CR1) and comparison with H, C4b-binding protein (C4bp), and decay accelerating factor (DAF).
    Seya T; Holers VM; Atkinson JP
    J Immunol; 1985 Oct; 135(4):2661-7. PubMed ID: 3161944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Further evidence for the antibody nature of C3 nephritic factor (C3NeF).
    Daha MR; van Es LA
    J Immunol; 1979 Aug; 123(2):755-8. PubMed ID: 379217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of C5 convertase activity by properdin, factors B and H.
    Weiler JM
    Immunol Res; 1989; 8(4):305-15. PubMed ID: 2531781
    [No Abstract]   [Full Text] [Related]  

  • 14. Regulation by membrane sialic acid of beta1H-dependent decay-dissociation of amplification C3 convertase of the alternative complement pathway.
    Fearon DT
    Proc Natl Acad Sci U S A; 1978 Apr; 75(4):1971-5. PubMed ID: 273923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two types of C3 nephritic factor: properdin-dependent C3NeF and properdin-independent C3NeF.
    Tanuma Y; Ohi H; Hatano M
    Clin Immunol Immunopathol; 1990 Aug; 56(2):226-38. PubMed ID: 2143128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Residual hemolytic and proteolytic activity expressed by Bb after decay-dissociation of C3b,Bb.
    Fishelson Z; Müller-Eberhard HJ
    J Immunol; 1984 Mar; 132(3):1425-9. PubMed ID: 6229580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of decay-accelerating factor on the assembly of the classical and alternative pathway C3 convertases in the presence of C4 or C3 nephritic factor.
    Ito S; Tamura N; Fujita T
    Immunology; 1989 Dec; 68(4):449-52. PubMed ID: 2481642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of the classical pathway C3 convertase by plasma proteins C4 binding protein and C3b inactivator.
    Gigli I; Fujita T; Nussenzweig V
    Proc Natl Acad Sci U S A; 1979 Dec; 76(12):6596-600. PubMed ID: 293746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preferential inactivation of the C5 convertase of the alternative complement pathway by factor I and membrane cofactor protein (MCP).
    Seya T; Okada M; Matsumoto M; Hong KS; Kinoshita T; Atkinson JP
    Mol Immunol; 1991 Oct; 28(10):1137-47. PubMed ID: 1833639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stabilization of homologous and heterologous cell-bound amplification convertases, C3bBb, by C3 nephritic factor.
    Daha MR; Van Es LA
    Immunology; 1981 May; 43(1):33-8. PubMed ID: 6166544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.